Bobak Youssefi
Psychiatric/Mental Health · Cambridge, OHNPI 1528671955
Payments from drug & device makers
Across 201 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$844
- Supernus Pharmaceuticals, Inc.$419
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$362
- Lundbeck LLC$202
- Sunovion Pharmaceuticals Inc.$199
- Alkermes, Inc.$196
- plus $920 from 11 others
What the payments were for
- Food & beverage$3,09599%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$175
How this compares
$3,142 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 92 | $138,496 |
| RexultiBrexpiprazole | 57 | $90,089 |
| Lurasidone Hcl | 89 | $25,223 |
| TrintellixVortioxetine Hydrobromide | 29 | $19,470 |
| Aripiprazole | 122 | $9,222 |
| Buspirone Hcl | 417 | $6,905 |
| Atomoxetine Hcl | 33 | $4,934 |
| Oxcarbazepine | 64 | $4,374 |
| Vilazodone Hcl | 27 | $4,006 |
| Duloxetine Hcl | 167 | $3,920 |
| Hydroxyzine Hcl | 216 | $2,897 |
| Bupropion XlBupropion Hcl | 176 | $2,735 |
| Trazodone Hcl | 309 | $2,213 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 65 | $2,188 |
| Divalproex Sodium ErDivalproex Sodium | 14 | $1,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $844 | $138,49692 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $125 | $90,08957 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $171 | $19,47029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Cambridge
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.